Table 1 Patient characteristics at baseline and virological treatment failure at month 6 and 12
Characteristics | All patients n = 874 | GRTa | NFLGb (n = 16) | |
|---|---|---|---|---|
Month 6 (n = 47) | Month 12 (n = 30) | |||
Gender: female/male | 527/347 (60/40%) | 23/24 (49/51%) | 17/13 (57/43%) | 5/11 (31/69%) |
Age: years (median, IQR) | 33 (11) | 30 (13) | 30 (9) | 31 (13) |
WHO clinical stage | ||||
 stage I | 149 (17.0%) | 4 (8.5%) | 3 (10.0%) | 1 (6.3%) |
 stage II | 223 (25.5%) | 13 (27.7%) | 8 (26.7%) | 5 (31.3%) |
 stage III | 372 (42.6%) | 19 (40.4%) | 12 (40.0%) | 6 (37.5%) |
 stage IV | 130 (14.9%) | 11 (23.4%) | 7 (23.3%) | 4 (25.0%) |
NRTI | ||||
 Tenofovir | 467 (53.4%) | 28 (59.6%) | 16 (53.3%) | 12 (75.0%) |
 Zidovudine | 362 (41.4%) | 15 (31.9%) | 10 (33.3%) | 4 (25.0%) |
 Stavudine | 44 (5.0%) | 4 (8.5%) | 4 (13.3%) | 0 (0.0%) |
NNRTI | ||||
 Nevirapine | 380 (43.5%) | 24 (51.1%) | 16 (53.3%) | 10 (62.5%) |
 Efavirenz | 494 (56.5%) | 23 (48.9%) | 14 (46.7%) | 6 (37.5%) |
Laboratory values | ||||
 CD4+ T-cells/μl: mean; SD | 143; 87 | 108; 80 | 113; 87 | 86; 76 |
 HIV RNA log10 copies/ml: mean; SD | 5.2; 0.8 | 5.4; 0.9 | 5.2; 1 | 5.8; 0.8 |